Labcorp
Labcorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
Alert:
Labcorp COVID-19 Antibody Testing Available Nationwide Learn more >>>
Special Instructions
This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.
Expected Turnaround Time
1 - 2 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
Specimen Requirements
Specimen
Serum or plasma
Volume
1 mL
Container
Red-top tube, gel-barrier tube, or lavender-top (EDTA) tube
Collection
If tube other than a gel-barrier tube is used, transfer separated serum or plasma to a plastic transport tube.
Storage Instructions
Room temperature
Stability Requirements
Temperature | Period |
|---|---|
Room temperature | 14 days |
Refrigerated | 14 days |
Frozen | 14 days |
Freeze/thaw cycles | Stable x3 |
Causes for Rejection
Non-EDTA plasma specimen; PST gel-barrier tube
Test Details
Use
Qualitative detection of antibodies to HCV. Per current guidelines, this test should not be used alone to screen for and diagnose HCV infection. HCV antibody positive patients should be tested for HCV RNA to differentiate between previous and active infection.
|
|
|
Qualitative detection of antibodies to HCV. Per current guidelines, this test should not be used alone to screen for and diagnose HCV infection. HCV antibody positive patients should be tested for HCV RNA to differentiate between previous and active infection. |
Limitations
Since as many as 90% of commercial intravenous immunoglobulins test positive for hepatitis C antibody, an artifactual positive can result briefly after transfusion.
Methodology
Enzyme immunoassay (EIA)
Additional Information
Following the development of sensitive and specific testing for hepatitis B, 90% of post-transfusion hepatitis is now hepatitis C. A gene product (c100) of hepatitis C virus (HCV) was isolated and an assay for anti-HCV developed. The assay detects antibody to a presumptive togavirus or flavivirus which may be an etiologic agent of non-A, non-B hepatitis (which may not be a unitary disease entity).
For blood donors, hepatitis C serology correlates with surrogate tests for non-A, non-B hepatitis (ALT and anti-HBc). Since hepatitis C serology identifies a broader group of infected individuals than surrogate testing, it reduces risk of HCV during transfusion. Studies in hemophiliacs indicate that antibody to HCV is a reliable marker of HCV.
References
American Association for the Study of Liver Diseases, Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. HCV Guidelines web site. https://www.hcvguidelines.org/evaluate/testing-and-linkage. Accessed December 2020.
Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137.26042815
|
A Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA. 1990 Nov 7; 264(17):2231-2235. 2170702 Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989 Apr 21; 244(4902):359-362. 2523562 Clemens JM, Taskar S, Chau K, et al. IgM antibody response in acute hepatitis C viral infection. Blood. 1992 Jan 1; 79(1):169-172. 1309424 Dodd LG, McBride JH, Gitnick GL, Howanitz PJ, Rodgerson DO. Prevalence of non-A, non-B hepatitis/hepatitis C virus antibody in human immunoglobulins. Am J Clin Pathol. 1992 Jan; 97(1):108-113. 1728850 Gambino R. NANB hepatitis−A new antibody test for the hepatitis C virus. Lab Report for Physicians. 1988; 10:89-93. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989 Apr 21; 244(4902):362-364. 2496467 Richards C, Holland P, Kuramoto K, Douville C, Randell R. Prevalence of antibody to hepatitis C virus in a blood donor population. Transfusion. 1991 Feb; 31(2):109-113.1847559 |
|
American Association for the Study of Liver Diseases, Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. HCV Guidelines web site. https://www.hcvguidelines.org/evaluate/testing-and-linkage. Accessed December 2020. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137.26042815 |
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 140659 | HCV Antibody | 48159-8 | 140689 | Hep C Virus Ab | s/co ratio | 48159-8 |
© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf